Viewing nowLamitin Tablets (Terbinafine Hydrochloride)
Terbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.

MFDS item code 200806414 · Notified 2008.06.11 · Insurance code 693200370
Treatment of onychomycosis and cutaneous fungal infections (e.g., tinea pedis), and tinea capitis
This medication is used for the treatment of dermatophytic infections and onychomycosis caused by dermatophytes such as tinea pedis, tinea corporis, and tinea cruris in adults. In children, it is used for treating tinea capitis. In other words, it is effective in improving various skin fungal infections and onychomycosis.
Administer terbinafine 125 mg per dose twice daily or 250 mg per dose once daily. The duration of administration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually administered for 6 weeks~3 months. In cases of infection of a fingernail or a relatively small toenail, or in younger patients, the treatment period may be shortened to 3 months or less. Treatment of toenail infections usually requires 3 months, but may take 6 months or longer in some patients. The treatment period may be longer in patients with slow nail growth. In patients with creatinine clearance less than 50 mL/min, reduce the daily dose by 1/2.
Administer to children 2 years of age and older. Use is not recommended in children under 2 years of age because there is no experience with administration. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for the prescribed duration. Body weight less than 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with treatment is limited, decide whether to administer after considering the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.
This medication is not recommended for patients with chronic liver disease or active liver disease. Before using this medication, liver health status should be checked, and liver function tests (AST/ALT) should be performed regularly before administration and 4-6 weeks after treatment. If liver function test values increase, this medication should be discontinued immediately. If any symptoms such as persistent nausea, appetite loss, fatigue, vomiting, pain in the upper right abdomen, jaundice, dark urine, or loose stools appear for no apparent reason during treatment with this medication, you should inform your doctor immediately, and stop administration if these symptoms occur and undergo liver function tests. Very rarely, liver failure may occur, so if liver damage is suspected, the medication should be discontinued immediately, and liver function should be closely monitored. This medication should not be used by individuals who have had allergic reactions to this medication or its ingredients, chronic liver disease, blood disorders, severe renal failure, nursing mothers, or infants under 2 years old. Since it contains lactose, patients with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption should not take it. Caution is advised in patients with severely impaired renal function, elderly patients, and children weighing less than 20 kg. If severe skin rashes or allergic reactions occur, discontinue use immediately. This medication should only be used for fungal infections that are difficult to treat topically, and activities such as driving or operating machinery should be avoided if symptoms like dizziness occur. There may be interactions with other medications, especially those metabolized in the liver or oral contraceptives, so it is important to consult a doctor or pharmacist in such cases. During pregnancy, safety is not established, and it should only be used when necessary, and nursing should be discontinued if breast-feeding. In case of overdose, symptoms such as headache, nausea, abdominal pain, and dizziness may occur, and immediate medical attention is needed. This medication should be kept out of the reach of children, not transferred to other containers, and stored at room temperature away from direct sunlight.
Liver and biliary system failure, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, malaise, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, subcutaneous bleeding, leukopenia, anemia, rash, itching, photosensitivity reaction, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, vesicular dermatitis, psoriasis-like rash, exacerbation of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, elevated serum myoglobin, elevated urinary myoglobin, hypotension, dyspnea, chest tightness, urticaria, erythema, facial swelling, lymphangiectasia, abdominal distension, decreased appetite, dyspepsia, mild abdominal pain, diarrhea, discomfort in the upper abdomen, thirst, vomiting, glossitis, depression, anxiety, headache, taste disorder, dizziness, drowsiness, sensory disturbance, decreased sensation, decreased attention, insomnia, elevated BUN, pollakiuria, visual impairment, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol, elevated triglyceride levels, malaise, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture entry, at room temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness and prevent deterioration.
White to almost colorless round tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowTerbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
GP Therapeutics Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Hutex Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Anguk Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Medica Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Gyeongnam Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Daehwa Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.